GlaxoSmithKline Plc agreed to pay more than $250 million to resolve about 5,500 claims related to its Avandia diabetes drug and avoid the first trial over claims it kills users, two people familiar with the accords said.
Glaxo, the U.K.'s biggest drugmaker, agreed to settle the lawsuits claiming the drug causes heart attacks for an average of at least $46,000 each, said the people, who declined to be identified because they weren't authorized to speak publicly.
The accords included a previously reported settlement of an undisclosed amount for the family of James Burford, an Avandia user who died in 2006. The Burford family's case, filed in federal court in Philadelphia, was set for trial last week.
Read the complete Bloomberg story, "Glaxo Said to Pay More Than $250 Million to Settle Avandia Death Lawsuits."